um hum...Script data from RBC releaed July 18 shows drugs they sell in North American all down (even recognizing that it was a shortened week). That makes me cautious expecting for too much in Q2. I think a longer term approach has to be taken if you want to hold this stock and if you believe that the company will continue to meet its debt obligations. The balance sheet is not great.